Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PCOS treatments put to the heart test

NCT ID NCT06889454

Knowledge-focused Sponsor: Attikon Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how different treatments for Polycystic Ovary Syndrome (PCOS) affect the heart and blood vessels. Researchers will compare four approaches: a GLP-1 receptor agonist, birth control pills, metformin, and lifestyle changes alone. They will measure changes in heart function and artery stiffness in 120 women with PCOS over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist, oral contraceptive, metformin, lifestyle modification
What this could lead to
If successful, this could help doctors choose PCOS treatments that also protect heart health.
What could go wrong
This is an early-stage study with only 120 participants, so results may not apply to all women with PCOS. It measures markers, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with PCOS

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 16 years old 2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following: * Clinical or biochemical hyperandrogenism * Anovulation or oligo-ovulation * Polycystic ovarian morphology (PCOM) 3. Absence of treatment for PCOS the last six months 4. Patients who have the ability to understand and sign the consent form. Exclusion Criteria: 1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \[17-OHP\]), Cushing syndrome, acromegaly 2. Treatment with contraceptive or metformin 3. Type 2 diabetes mellitus 4. Treatment for diabetes 5. Pregnancy 6. Lactation 7. Malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperandrogenism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Hyperandrogenism hyperinsulinism metabolic syndrome X polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperandrogenism Hyperinsulinism Metabolic syndrome PCOS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Attikon University General Hospital

    RECRUITING

    Chaïdári, 124 62, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.